The HOPE TIPS: The HOPE study translated into practices

Cardiovascular Drugs and Therapy

Volumn 19, Issue 3, 2005, Pages 197-201

  Sharpe, Norman ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b NONE   (New Zealand)

Author keywords

Cardiovascular risk; Diabetes; Ramipril

Indexed keywords

RAMIPRIL;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEART INFARCTION; HEART PALPITATION; HEART RATE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VOMITING;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; COUGH; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RAMIPRIL;

EID: 24344456502     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-005-1375-1     Document Type: Article

References (13)

1. Murray CJL, Lopez AD, eds. The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston: Harvard School of Public Health, 1996.
2. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-953.
3. Third Joint Task Force of the European and other Societies. European guidelines on cardiovascular disease prevention in clinical practice. New Euro J CV Prev and Rehab 2003;10(Suppl 1):S11-S78.
4. New Zealand Guidelines Group. The Assessment and Management of Cardiovascular Risk. December 2003.
5. Heart Outcomes Prevention Evaluation (HOPE) study investigators. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
6. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary heart disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
7. The PEACE Trial Investigators. Angiotensin converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-2068.
8. Antithrombotic Trialists' Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324:71-86.
9. Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction: An overview of the randomised trials. Prog Cardiovasc Dis 1985;27:335-371.
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival (4S) Study. Lancet 1994;334:1383-1389.
11. Evaluation (HOPE) study. Eur Heart J 2001;22:103-104.
12. Sharpe N. Matching the standards of clinical trial evidence with application in practice. Int J Clin Pract 2002;56:772-775.
13. Kaplan NM. The CARE study, a postmarketing evaluation of ramipril in 11,100 patients. Clin Ther 1996;18:658-670.